High humidity decreases symptomatic patent ductus arteriosus

A phase II clinical trial to examine the preventive effects of high humidity control on the patent ductus arteriosus - High humidity decreases symptomatic patent ductus arteriosus

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1032190068

Enrollment

Registered

2019-08-05

Start date

2019-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

extremely premature infant, patent ductus arteriosus

Interventions

High humidity care will be started within 6 hours after admission. Humidity inside the incubator will be kept at 90% until 72 hours after birth. After that, the humidity will be decreased 5% per day

D006813

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Preterm infants at gestational weeks of 24 to 27 who admitted to neonatal intensive care unit at Yokohama city university medical center

Exclusion criteria

Exclusion criteria: congenital abnormality severe asphyxia (APGAR score 4 points or less at 5 minutes) twin to twin transfusion syndrome apparent at birth birth at another hospital birth from underage and unmarried mother

Design outcomes

Primary

Measure	Time frame
The incidence of symptomatic patent ductus arteriosus within 7 days from birth	—

Secondary

Measure	Time frame
Total amount of indomethacin administered until 14 days after birth. Maximum ascent rate of serum sodium concentration until 7 days after birth or until the onset of the symptomatic patent ductus arteriosus. The incidence of hypernatremia (Na > 145mEq/L) until 7 days after birth.	—

Contacts

Public ContactMichisato Hirata

Yokohama City University Medical Center

mh7160@yokohama-cu.ac.jp+81-45-261-5656

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026